We're sorry, but your browser is no longer supported.

To improve your experience on our site and ensure your security, please upgrade to a modern browser Google Chrome, Mozilla Firefox or Microsoft Edge.

For more information click here.

PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023